BMO Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $17
Jefferies Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $11.5
Chemours Is Maintained at Outperform by RBC Capital
Chemours Analyst Ratings
RBC Cuts Price Target on Chemours to $14 From $17, Keeps Outperform Rating
Truist Financial Maintains The Chemours(CC.US) With Buy Rating
UBS Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $17
Mizuho Securities Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $13
Chemours Is Maintained at Buy by UBS
Chemours Analyst Ratings
Alembic Global Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $18
Research Alert: Chemours Reports Mixed Q1 Results, Lowers Top End Of Fy 25 Guidance Slightly
Mizuho Securities Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $15
Truist Financial Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $22
Chemours Is Maintained at Buy by Truist Securities
Chemours Analyst Ratings
RBC Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $17
UBS Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $18
BMO Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $21
Chemours Is Maintained at Equal-Weight by Barclays